Steven C. Gilman's most recent trade in Scynexis Inc was a trade of 23,000 Stock Option done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 23,000 | 23,000 | - | - | Stock Option | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 23,000 | 70,000 (0%) | 0% | 0 | Common stock | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 53,600 | 53,600 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 35,700 | 152,830 (0%) | 0% | 0 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 16 Oct 2024 | 5,833 | 11,000 (0%) | 0% | 41.4 | 241,253 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 16 Oct 2024 | 5,833 | 0 | - | - | Stock Option (Right to Buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 16 Oct 2024 | 5,833 | 16,833 (0%) | 0% | 13.1 | 76,121 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 02 Oct 2024 | 5,833 | 11,000 (0%) | 0% | 40.4 | 235,362 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 02 Oct 2024 | 5,833 | 16,833 (0%) | 0% | 13.1 | 76,121 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 02 Oct 2024 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 18 Sep 2024 | 5,834 | 16,834 (0%) | 0% | 13.1 | 76,134 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 18 Sep 2024 | 5,834 | 11,666 | - | - | Stock Option (Right to Buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 18 Sep 2024 | 5,834 | 11,000 (0%) | 0% | 45.5 | 265,680 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 04 Sep 2024 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 04 Sep 2024 | 5,000 | 11,000 (0%) | 0% | 48.6 | 242,900 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 04 Sep 2024 | 5,000 | 16,000 (0%) | 0% | 3.7 | 18,700 | Common Stock | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 47,000 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,000 | 117,130 (0%) | 0% | 0 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 01 May 2024 | 8,000 | 8,000 | - | - | Stock Option (Right to Buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 01 May 2024 | 3,200 | 11,000 (0%) | 0% | - | Common Stock | ||
| Vericel Corp | Steven C. Gilman | Director | 01 May 2024 | 3,200 | 3,200 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 01 May 2024 | 3,200 | 0 | - | - | Restricted Stock Unit | ||
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 30,000 | 87,130 (0%) | 0% | 0 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 03 May 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 03 May 2023 | 3,200 | 3,200 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2023 | 2,600 | 0 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2023 | 2,600 | 7,800 (0%) | 0% | - | Common Stock | ||
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 14,000 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 13,700 | 57,130 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 03 Jun 2022 | 4,567 | 43,430 (0%) | 0% | 0.4 | 1,653 | Common Stock |
| ContraFect Corp | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 42,000 | 42,000 | - | - | Options (Right to Buy) | |
| Vericel Corp | Steven C. Gilman | Director | 29 Apr 2022 | 900 | 5,200 (0%) | 0% | 30.9 | 27,846 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2022 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2022 | 2,600 | 6,100 (0%) | 0% | - | Common Stock | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2022 | 2,600 | 2,600 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Apr 2022 | 2,600 | 0 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 29 Nov 2021 | 5,000 | 3,500 (0%) | 0% | 39.2 | 195,855 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 29 Nov 2021 | 5,000 | 0 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 29 Nov 2021 | 5,000 | 8,500 (0%) | 0% | 3.7 | 18,700 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 27 Oct 2021 | 5,000 | 3,500 (0%) | 0% | 50.6 | 252,870 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 27 Oct 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 27 Oct 2021 | 5,000 | 8,500 (0%) | 0% | 3.7 | 18,700 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 30 Sep 2021 | 5,000 | 3,500 (0%) | 0% | 48.9 | 244,255 | Common Stock | |
| Vericel Corp | Steven C. Gilman | Director | 30 Sep 2021 | 5,000 | 10,000 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 30 Sep 2021 | 5,000 | 8,500 (0%) | 0% | 3.7 | 18,700 | Common Stock | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Sale of securities on an exchange or to another person at price $ 3.32 per share. | 07 Jun 2021 | 4,567 | 47,997 (0%) | 0% | 3.3 | 15,163 | Common Stock |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,700 | 52,564 (0%) | 0% | 0 | Common Stock | |
| ContraFect Corp | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 25,000 | 25,000 | - | - | Options (Right to Buy) | |
| Vericel Corp | Steven C. Gilman | Director | 28 Apr 2021 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | ||
| Vericel Corp | Steven C. Gilman | Director | 28 Apr 2021 | 2,600 | 2,600 | - | - | Restricted Stock Unit | ||
| Vericel Corp | Steven C. Gilman | Director | 28 Apr 2021 | 1,750 | 3,500 (0%) | 0% | - | Common Stock | ||
| Vericel Corp | Steven C. Gilman | Director | 28 Apr 2021 | 1,750 | 0 | - | - | Restricted Stock Unit | ||
| Scynexis Inc | Steven C. Gilman | Director | Purchase of securities on an exchange or from another person at price $ 6.25 per share. | 21 Dec 2020 | 4,000 | 4,000 (0%) | 0% | 6.3 | 25,000 | Common Stock |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 2,000 | 2,000 | - | - | Common Stock Warrant | |
| Scynexis Inc | Steven C. Gilman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2020 | 2,000 | 2,000 | - | - | Common Stock Warrant |